AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
AIVITA Biomedical CEO Dr. Hans Keirstead to Moderate Keynote Panel of Pharma Industry Leaders at World Vaccine Congress EU>
AIVITA Biomedical CEO Dr. Hans Keirstead to Participate in Keynote Panel and Deliver Talk at Festival of Biologics Europe
AIVITA Biomedical CEO Dr. Hans Keirstead to Moderate Keynote Panel of Pharma Industry Leaders at World Vaccine Congress EU>
AIVITA Biomedical CEO Dr. Hans Keirstead to Participate in Keynote Panel and Deliver Talk at Festival of Biologics Europe